“ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform, today announced it has enrolled the first patient into the "Brighton" study, a Phase 2 clinical trial evaluating PNT2258 in patie
“ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform, today announced it has enrolled the first patient into the "Brighton" study, a Phase 2 clinical trial evaluating PNT2258 in patie
このブックマークにはスターがありません。
最初のスターをつけてみよう！
ProNAi Initiates 'Brighton' Phase II Trial of PNT2258 in Patients with Richter's Transformation
1 人がブックマーク・1 件のコメント
＼ コメントが サクサク読める アプリです ／